Statins and risk of incident diabetes

The Lancet

Volumn 375, Issue 9732, 2010, Pages 2139-

  McEvoy, John W ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANALYTICAL ERROR; CLINICAL TRIAL; DIABETES MELLITUS; HAZARD RATIO; HUMAN; INCIDENTAL FINDING; LETTER; POST HOC ANALYSIS; PRIORITY JOURNAL; SAMPLE SIZE; SURVIVAL RATE;

EID: 77953568985     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60985-3     Document Type: Letter

References (5)

1. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375 (2010) 735-742
2. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103 (2001) 357-362
3. Ellis J.J., Erickson S.R., Stevenson J.G., Bernstein S.J., Stiles R.A., and Fendrick A.M. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 19 (2004) 638-645
4. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
5. Kaul S., and Diamond G.A. Trial and error: how to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol 55 (2010) 415-427